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Abstract
The  BRAF  mutant  colorectal  cancer  subgroup  is  a  small  population  with  unique
clinicopathological and molecular features. This subgroup has been associated with
particularly poor prognosis and advanced disease. The poor response of these patients
to available treatments has driven much of the effort in trialling combination targeted
treatments involving BRAF and MEK inhibitors. Most recently, an observed survival
benefit with intensive triplet chemotherapy agents would encourage its use as first-line
treatment in suitable candidates given that few of these patients proceed to second- or
third-line treatments.
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1. Introduction
The BRAF mutant (MT) colorectal cancer (CRC) population is a small and unique subgroup
noted for its association with poor prognosis and survival. BRAF mutation occurs in approxi‐
mately 10% (range, 5–22%) [1, 2] of the unselected CRC population and consistently has inferior
median survival outcomes ranging from 8 to 14 months [3, 4]. Failure to achieve good surviv‐
al outcomes through standard doublet chemotherapy agents in this population has ignited
efforts to combine multiple target therapies, aiming for breakthroughs. In this chapter, the BRAF
gene and its signalling pathway are explored in detail. BRAF gene mutation frequency and its
impact on clinical presentation as well as its prognostic and predictive significance are also
discussed. Updates on the current and latest management strategies as well as novel investiga‐
tional treatments in this subgroup are also presented.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. BRAF and the RAS/RAF/MEK/ERK signalling pathway
V-raf murine sarcoma viral oncogene homologue (RAF) is one of the most intensively
researched mammalian effectors of RAS in the RAS/RAF/MEK/ERK signalling pathway
(Figure 1) [5, 6]. The RAF protein itself is made up of three conserved regions: CR1, CR2, and
CR3. CR1 and CR2 are situated in the N terminus. CR1 acts as the main binding domain for
RAS. CR2 is the regulatory domain. CR3 is situated at the C terminus and functions as the
catalytic kinase domain [7].
When GTP bound, RAS recruits RAF protein to the cell membrane and binds to it. This binding
process activates RAF kinase by the phosphorylation of two amino acids (T599 and S602 of
BRAF) situated in the activation segment of the kinase domain. RAF then phosphorylates its
downstream effectors MEK1, MEK2, ERK1, and ERK2, leading to the activation of cellular
proliferation, differentiation, and transcriptional regulation (Figure 1) [7].
Figure 1. RAS and PIK3CA signalling pathways.
B-RAF (BRAF) together with A-RAF and C-RAF are the members of the RAF kinase family [8].
These three RAF isoforms are homologous in sequence and substrate specificity but do differ
in their biological functions and regulations. Of these, BRAF remains the most potent activator
of MEK [9].
The BRAF gene is a proto-oncogene located on chromosome arm 7q34, composed of 18 exons.
There are more than 30 different BRAF mutations [10]. The most common activating mutation,
Colorectal Cancer - From Pathogenesis to Treatment90
BRAF V600E (p.Val600Glu/c.1799T>A), accounts for 90% of all activating BRAF mutations and
is found in exon 15 at nucleotide position 1799 [11]. The thymine-to-adenine transversion
within codon 600 leads to the substitution of valine by glutamate at the amino acid level. This
mutation occurs in the activating segment of the kinase domain, resulting in increased basal
kinase activity. Compared to wild-type (WT) BRAF, BRAF V600E demonstrates an almost 500-
fold increase in endogenous kinase activity [10, 12].
In solid tumours, the highest incidence of BRAF mutations is in malignant melanoma (27–70%),
CRC (5–22%), and serous ovarian cancer (~30%) and less (1–3%) in non-small cell lung
carcinoma (NSCLC) [13–15]. In colonic cell lines, the oncogenic effects of BRAF V600E include
cell proliferation and inhibition of apoptosis [16]. Although dependent on continued BRAF
activity for tumourigenic growth, BRAF MT cells did not require an upstream RAS function
for proliferation [17].
2.1. BRAF mutation detection methods
CRC BRAF mutations can be identified using first- and second-generation direct sequencing,
immunohistochemistry (IHC), and, potentially, circulating tumour cells (CTC).
Sanger sequencing is the earliest form of first-generation direct sequencing. Sanger sequencing
was developed in 1975 and relies on the chain-termination sequencing of amplified DNA by
polymerase chain reaction (PCR) and detection through electrophoresis. It requires approxi‐
mately 18 to 19 h to process and is also 10 times less sensitive than pyrosequencing. Sanger
sequencing method also cannot detect the changes in chromosomal copy number and trans‐
locations [18].
Next-generation sequencing (NGS) differs in technology using a specific reagent wash of
nucleotide triphosphates with synchronised optical detection and includes pyrosequencing,
allele-specific (AS) PCR, mass spectrometry, and real-time qPCR with melt-curve analysis [19].
NGS is the new gold standard test in BRAF mutation detection given its superior detection
and speed.
Pyrosequencing is referred to as sequencing by synthesis and relies on the release of pyro‐
phosphate (PPi) by DNA polymerase. The test detects light emitted when nucleotides are
added to the target DNA template by DNA polymerase releasing PPi via a chemiluminescence
reaction. It is a more rapid and sensitive test in detecting BRAF V600E mutations in addition
to other variants such as V600D, V600K, V600R, and K601E. It can provide the percentage of
DNA that harbours the BRAF V600E mutations. However, this method is limited by the length
of DNA template and is prone to error readings in homopolymer sequences (TTTTTTTT) [18].
AS-PCR enriches known mutations in samples to increase the sensitivity of detection and is
particularly useful in tissue with low tumour content. Mass spectrometry-based sequencing
relies on the analysis of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-
TOF). This process is facilitated by the addition of mass-modified bases A, C, T, and G to the
primed and amplified mutational hotspots. It is this flight time difference of the generated
mass-modified complex that is measured by the mass spectrometer. Mass spectrometry-based
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sequencing is an even more sensitive test compared to pyrosequencing, with a detection ratio
of 1:10 and 1:8, respectively [18].
Melt-curve analysis involves detecting the melting temperature for WT BRAF at 61°C and the
V600E MT melting at 53°C. PCR methods, on the contrary, can perform as well and has
advantages in terms of reduced labour (1.25 vs 16 min), faster turnaround (4 min vs 10 h), and
lower cost ($2.6 vs $10.4). The sensitivity and specificity of real-time qPCR is reported to be
100% [19]. Table 1 details the comparisons among some of the available NGS techniques.
Method Sensitivity Accuracy Time Cost/1
mill bases
(USD)
Advantages/
disadvantages
Chain termination
(Sanger)
Low 99.9% 20 min–3 h 2400 Requires the time-consuming
step of PCR of plasmid cloning;
impractical for larger sequencing
projects
Pyrosequencing
(454)
Medium 99.9% 24 h 10 Homopolymer errors
Sequencing by
synthesis (Illumina)
High 99.9% 1–11 days 0.05–0.15 Expensive equipment;
requires high DNA
concentrations
Sequencing by
ligation
High 99.9% 1–2 weeks 0.13 Slower; issues sequencing
palindromic sequences
Ion semi
conductor
High 98% 2 h 1 Homopolymer errors
Single-molecule
real-time sequencing
High 87% 30 min–4 h 0.13–0.60 Expensive equipment;
moderate throughput
Table 1. Available NGS techniques in detecting BRAF V600E mutation [20, 21].
The IHC detection of BRAF V600E with a mutation-specific antibody (clone VE1) was first
described in metastatic melanoma and papillary thyroid carcinoma and is currently commer‐
cially available [22]. The advantage of IHC lies in the minimal amount of tissue needed and
the availability of this technique in most pathological laboratories. Most studies have reported
high sensitivities and specificities (98.8–100%) compared to PCR-based methods or sequencing
[23–25]. However, there is one study that has reported sensitivity and specificity of only 71%
and 74%, respectively [26]. The choice of positive control tissue and the amplification protocol
is regarded to be crucial in the successful detection of BRAF mutation by IHC [27].
Recently, examination of CTC in peripheral blood has been explored as a new non-invasive
means for detecting BRAF mutation in CRC [28]. Blood collected from 44 patients was enriched
for CTC using a size-based microsieve technology. By incorporating the high-resolution melt-
curve analysis technique, the concordance rates between CTC and tumour mutations were
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observed to be 90.9% (p=0.174) for BRAF mutation genotype status and 84.1% (p=0.000129) for
KRAS mutation genotype status.
2.2. BRAF mutation and its frequency in CRC
A meta-analysis of 10 studies reported BRAF mutations in 4.8% to 20.8% of CRC [74]. Table 2
further details the BRAF mutation rates and the corresponding detection methods in some
notable metastatic CRC (mCRC) trials.
CRC trials BRAF MT frequency Method
PRIME [29, 30] 8% Bidirectional Sanger sequencing
FIRE-3 [31] 10.5% pyrosequencing
CRYSTAL [4] 6% PCR clamping/melt-curve analysis
MAX [3] 10.6% High-resolution melting point/PCR
PICCOLO [32] 14.8% PCR/pyrosequencing
NORDIC-VII [33] 12% Wobble enhanced ARMS*/real-time PCR
AGITG/NCIC CO.17 [59] 3.2% (overall) and 4.8% (KRAS WT) PCR/sequencing
COIN [34] 8% MALDI-TOF (Sequenom)/Sanger sequencing
TRIBE [35] 7.5% Pyrosequencing
Table 2. BRAF mutation detection methods and reported frequencies in notable CRC trials.
Figure 2. Somatic mutation frequencies in CRC.
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Importantly, BRAF MT CRC is reported to be mutually exclusive to KRAS mutation [36]. BRAF
mutation coexists with PIK3CA mutations in 13% and PTEN mutations in 22% of CRC [37].
Figure 2 depicts the frequency of the different somatic mutations discovered in CRC pa‐
tients.Chan, E. My Cancer Genome. Molecular Profiling of Colorectal Cancer [Internet].
January 26, 2016 [Updated:January 26, 2016]. Available from: https://www.mycancerge‐
nome.org/content/disease/colorectal-cancer/ [Accessed: January 26, 2016].
3. BRAF mutation and its clinical significance in CRC
3.1. CRC tumourigenesis pathways
The two main separate pathways observed in CRC development and progression are the
chromosomal instability pathway (CIN), which accounts for 75% of the cases, and the micro‐
satellite instability (MSI) pathway in 25% of the cases. Two processes are observed to contribute
towards the MSI pathway: (1) germ-line mutations from Lynch syndrome and (2) sporadic
MLH1 methylation from the serrated methylated pathway (Figure 3) [38] [100].
Figure 3. CRC tumourigenesis pathways.
The CIN pathway involves a defect in replication, mitosis, or DNA repair leading to genetic
abnormalities, both structural and numeric, which are acquired sequentially. As a result,
oncogenes are activated or tumour suppressor gene function is lost, which contributes towards
malignant growth. This pathway is also often associated with aneuploidy by karyotyping. The
genetic changes found in CRC arising via the CIN pathway include APC mutations (90%),
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KRAS mutation (50%), TP53 mutations (70%), and allelic loss of 18q (80%) [39]. The CIN
pathway has been traditionally associated with CRC arising in adenomatous polyps.
The MSI pathway is a result of defective mismatch repair (MMR) and occurs in a subset of
CRC that arise from either adenomas or serrated polyps. It contributes towards tumour
progression via the accumulation of tiny insertions and deletions in the repetitive sequences
of microsatellites in coding genes, thereby retaining a near-diploid karyotype. This mechanism
of tumourigenesis is readily recognized through a test for MSI, which categorises each tumour
as MSI-high (MSI-H), MSI-low (MSI-L), or microsatellite stable (MSS), based on the proportion
of microsatellites mutated. MSI-H cases usually imply an acquired or inherited defect in DNA
repair.
In inherited cases of MSI-H CRC, germ-line mutation in one of the four genes that encode
proteins responsible for MMR (MLH1, MSH2, PMS2, and MSH6) is responsible for a familial
predisposition to cancer. This familial predisposition to CRC is known as Lynch syndrome
[40], and the CRC that arise in this condition develop in adenomas.
In sporadic cases of MSI-H CRC, the serrated methylated pathway is increasingly implicated.
Serrated polyps, not driven by CIN but by BRAF mutations, are observed to replace adenomas
as precursor lesions in CRC. MSI-H CRC occur due to the epigenetic inactivation of MLH1 by
promoter methylation, which prevents MLH1 protein expression, resulting in defective MMR
and producing MSI. This pathway is also closely associated with the widespread methylation
of CpG islands, causing the transcriptional silencing of tumour suppressor genes, known as
the CpG island methylator phenotype (CIMP) [38, 39].
3.2. BRAF testing to distinguish between sporadic versus germ-line MSI-H cases (Lynch
syndrome)
Approximately 12% of MSI-H cases are sporadic in nature and BRAF mutation is implicated
in nearly all (91%) of these cases [41, 42]. The methylation of MLH1 is found only in 1.6% of
germ-line Lynch syndrome cases [43], whereas it is typically found in sporadic tumour lacking
MLH1 expression [44]. Hence, BRAF mutation testing is recommended in MSI-H CRC as a
triage for Lynch syndrome. Only those lacking the BRAF mutation proceed with further
workup for Lynch syndrome, as CRC harbouring the BRAF mutation are, with few exceptions,
unlikely to have this condition.
MLH1 methylation testing is an alternative assay to distinguish sporadic from familial cases
of CRC. However, given that methylation testing is more technically challenging than BRAF
mutation testing, most would advocate BRAF testing as the more cost-effective assay to
distinguish sporadic from familial MSI-H CRC [44].
3.3. Clinicopathological and molecular features of BRAF MT CRC
BRAF mutation has been reported in multiple studies to be associated with several clinicopa‐
thological parameters in CRC patients. BRAF V600E mutation is reported to increase from 10%
in unselected patients to 37% in females ages >70 years [45]. BRAF mutations in the Western
population tend to be more common in females and to have a more proximal location in the
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colorectum [27, 46–52]. BRAF mutations are rarely found in the left-sided colon (4%) and rectal
cancers (2%) compared to the right-sided colon (22%; p<0.0001) [53]. BRAF mutation also varies
by pathology. Approximately 60% of BRAF MT tumours are poorly differentiated and only
up to 36% of them are well to moderately differentiated. Mucinous cancers tend to have a
higher rate of BRAF mutation (22–67%) compared to non-mucinous cancers (6–21%) [39, 54,
55].
The relationship between BRAF mutation and these clinicopathological features was con‐
firmed in a meta-analysis reported in 2014 [36]. Twenty-five studies of 11,955 CRC patients
were included in this analysis. The mutation rate was seen to vary with the highest reported
at 21.8% [2], the lowest being 5.0% [1], and the overall rate being 10.8%. Nine of the 25 studies
have shown that BRAF mutation was associated with advanced tumor-node-metastasis (TNM)
stage at diagnosis [11.6% in stage III/IV CRC vs 8.0% in stage I/II CRC; odds ratio (OR)=1.59;
95% confidence interval (CI)=1.16–2.17]. Thirteen of these studies showed that BRAF MT CRC
was more prevalent in poorly differentiated tumours than well to moderately differentiated
tumours. Of 766 patients with poorly differentiated tumours, 25.6% were BRAF MT, whereas
only 8% of 4257 patients with well to moderately differentiated tumours were BRAF MT
(OR=3.89; 95% CI=2.94–5.17). Six studies have also shown that more BRAF MT were detected
in the mucinous subgroup than in the non-mucinous subgroup (19.4% vs 8.1%; OR=2.99; 95%
CI=2.20–4.07). Twenty studies have also significantly demonstrated that proximal cancers
(21.6%) harbour more BRAF mutations than distal cancers (4.8%; OR=4.85; 95% CI=3.59–6.56)
[36].
Another study [56] reported a significantly increased rate of peritoneal (46% vs 24%; p<0.001)
and distant lymph node metastases (53% vs 38%; p=0.001) and a lower rate of lung metastases
(35% vs 49%; p=0.049) in BRAF MT CRC compared to BRAF WT tumours that might help to
explain their poor prognosis.
Clinicopathological features of BRAF V600E MT CRC patients Molecular features of BRAF V600E MT CRC
1. Age >70 years 1. More prevalent in MSI-H>MSS CRC
2. Female patients 2. More CIMP
3. Proximal right-sided tumours 3. More MLH-1 methylation
4. High-grade and poorly differentiated 4. Mutually exclusive to KRAS mutation
5. Mucinous>non-mucinous
6. More peritoneal and lymph node metastases
7. Less lung metastases
Table 3. Clinicopathological and molecular characteristics of BRAF V600E MT CRC
Relationships between BRAF MT and some molecular characteristics were also reported [36].
BRAF MT were significantly more prevalent in MSI-H CRC (38.9%) than MSS CRC (9.3%;
OR=8.18; 95% CI=5.08–13.17). As mentioned above, CIMP characterized by widespread
Colorectal Cancer - From Pathogenesis to Treatment96
aberrant DNA methylation at select CpG islands was implicated in a minority of CRC
tumourigenecity cases. Two studies were analysed for CIMP status and demonstrated a
positive relationship with BRAF MT CRC: 45.9% (CIMP) vs 9.1% (non-CIMP; (OR=16.44; 95%
CI=6.72–40.21). The methylation of the MLH1 promoter region is an underlying cause of
sporadic non-Lynch cases of MSI-H CRC. Three studies reported a relationship between BRAF
MT and MLH1 methylation status; 62.5% of MLH1 methylated CRC had BRAF mutations
compared to 9.2% of non-methylated CRC (OR=13.84; 95% CI=1.75–109.24). BRAF MT and
KRAS MT were found to be mutually exclusive in this meta-analysis.
Table 3 summarises the clinicopathological and molecular characteristics of BRAF MT CRC.
4. BRAF mutation and its prognostic and predictive significance
4.1. Prognostic role and nature of progression
Multiple studies have reported poorer median overall survival (OS) in the BRAF MT mCRC
subgroup. Regardless of treatment modality, median survival is generally reported to be
between 10 and 16 months shorter than the overall population. For instance, the COIN trial,
which studied 1630 patients for the effect of cetuximab and doublet chemotherapy FOLFOX
in mCRC patients, had reported a median OS of 8.8 months in BRAF MT patients versus 20.1
months in patients with (BRAF and RAS) WT [34]. The PRIME study had reported a median
OS of 10.5 months in the BRAF MT/RAS WT subgroup, contrasting to a median OS of 25.8
months in RAS WT group and 15.5 months in the RAS MT group. In this study, both (BRAF
and RAS) WT patients also had the longest median OS of 28.3 months [29]. The pooled analysis
of CRYSTAL and OPUS had also reported lower median OS in the BRAF MT group compared
to the BRAF WT group (9.9 vs 21.1 months in the chemotherapy arm and 14.1 vs 24.8 months
in the chemotherapy in combination with cetuximab arms) [57]. In 2013, the PLoS ONE meta-
analysis analysed 21 mCRC trials of 5229 patients treated with monoclonal antibodies [58].
Fourteen of these trials were retrospective; two trials were prospective and five trials were
randomised-controlled trials (RCTs). BRAF mutation was detected in 7.4%. Patients with BRAF
WT showed decreased risks of progression and death with an improved progression-free
survival [PFS; hazard ratio (HR)=0.38; 95% CI=0.29–0.51] and an improved OS (HR=0.35; 95%
CI=0.29–0.42) compared to BRAF MT. Compared to BRAF WT patients, the updated prognostic
analyses from the TRIBE study in 2014, which compared standard doublet chemotherapy to
triplet chemotherapy, also reported significantly shorter PFS and OS, in the BRAF MT group
in unresectable mCRC patients, independent of the treatment received [35]. Table 4
summarises the reported median OS in the BRAF MT CRC subgroup reported from various
phase III trials. It is also noted here that the BRAF mutation rates decrease with lines of therapy,
signifying the reducing likelihood of BRAF MT patients surviving long enough to receive
further lines of treatment.
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Study No. of
patients
Treatment
line/arm
BRAF
MT
rate
BRAF MT
median PFS
(months)
BRAF MT
median OS
(months)
KRAS WT
median PFS
(months)
KRAS WT
median OS
(months)
CRYSTAL (2011) [4] 1198 First line: FOLFIRI
vs cetuximab+
FOLFIRI
6% 5.6 vs 8.0
(HR=0.93;
p=0.87)
10.3 vs 14.1
(HR=0.91;
p=0.74)
8.8 vs 10.9
(HR=0.67;
p=0.001)
21.6 vs 25.1
(HR=0.83;
p=0.055)
PRIME (2013) [29,
30]
1183 First line: FOLFOX
vs panitumumab+
FOLFOX
8% 5.4 vs 6.1
(HR=0.58;
p=0.12)
9.2 vs 10.5
(HR=0.90;
p=0.76)
RAS/BRAF
WT 9.2 vs 10.8
(HR=0.68;
p<0.01)
RAS/BRAF
WT 20.9 vs
28.3 (HR=0.74;
p=0.02)
FIRE-3 (2013) [31] 400 First line: Avastin
+FOLFIRI vs
cetuximab+FOLFIRI
10.5% 6 vs 4.9
(HR=0.87;
p=0.65)
13.7 vs 12.3
(HR=0.87;
p=0.65)
RAS WT
10.2 vs 10.4
(HR=0.93;
p=0.54)
RAS WT
25.6 vs 33.1
(HR=0.70;
p=0.011)
COIN
(2011) [34]
1630 First line: FOLFOX/
XELOX vs cetuximab
+FOLFOX/XELOX
8% 5.6 vs 9.0
(RAS/BRAF
WT) p<0.0001
8.8 vs 14.4
(KRAS MT)
p<0.001
8.6 vs 8.6
(HR=0.96;
p=0.60)
17.9 vs 17.0
(HR=1.04;
p=0.67)
NORDIC-
VII (2012) [33]
566 First line: NORDIC
FLOX+cetuximab vs
FLOX alone vs
intermittent FLOX
+cetuximab
12% 5.1 vs 8.3
(BRAF WT)
p<0.001
9.5 vs 22
(BRAF WT)
p<0.001
8.7 vs 7.9 vs
7.5 (HR=1.07;
p=0.66)
22.0 vs 20.1
vs 21.4
(HR=1.08–1.14;
p=0.77–0.80)
CO.17
(2013) [59]
572 Chemorefractory:
cetuximab vs BSC
3.2% Median PFS
not reported
(HR=0.76;
p=0.69)
1.77 vs 2.97
(HR=0.84;
p=0.81)
Favours
cetuximab
(HR=0.4;
p<0.001)
9.7 vs 5.0
(HR=0.52;
p<0.0001)
MAX
(2011) [3]
471 First line: capecitabine
(C) vs capecitabine/
bevacizumab (CB) or
capecitabine/
bevacizumab/
mitomycin (CBM)
10.6% 2.5 vs 5.5
(HR=0.86;
p=0.71)
6.3 vs 9.2
(HR=0.67;
p=0.34)
5.9 vs 8.8
(HR=0.66;
p=0.006)
20 vs 19.8
(HR=0.86;
p=0.38)
PICCOLO
(2013) [32]
460 Second line: irinotecan
vs irinotecan/
panitumumab (IrPan)
14.8% Favours
irinotecan
(HR=1.40;
p=0.018)
Favours
irinotecan
(HR=1.84;
p=0.029)
Favours
IrPan (~6M)
(HR=0.78;
p=0.015)
10.5 vs 10.4
(HR=1.01;
p=0.91)
181
Peeters M, Oliner
KS, Price TJ,
Cervantes A, Sobrero
AF, Ducreux M, et al.
1015 Second line: FOLFIRI
vs panitumumab/
FOLFIRI
4.4% RAS WT
1.8 vs 2.5
(HR=0.69;
p=0.34)
RAS WT
5.7 vs 4.7
(HR=0.64;
p=0.20)
RAS WT
5.5 vs 6.9
(HR=0.68;
p=0.006)
RAS WT
15.4 vs 18.7
(HR=0.83;
p=0.15)
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Study No. of
patients
Treatment
line/arm
BRAF
MT
rate
BRAF MT
median PFS
(months)
BRAF MT
median OS
(months)
KRAS WT
median PFS
(months)
KRAS WT
median OS
(months)
Updated analysis of
KRAS/NRAS and
BRAF mutations in
study 20050181 of
panitumumab
(pmab) + FOLFIRI
for 2nd-line
treatment (tx) of
metastatic colorectal
cancer (mCRC). J
Clin Oncol
2014;32(Suppl.).
Abstract 3568.
TRIBE
(2015) [35]
508 First line: Avastin/
FOLFIRI vs Avastin/
FOLFOXIRI
7.5% 5.5 vs 7.5
(HR=0.56)
10.8 vs 19.1
(HR=0.55)
RAS WT
11.3 vs 13.3
(HR=0.77)
RAS WT
34.4 vs 41.7
(HR=0.84)
Table 4. Poorer survival in BRAF MT CRC and mutation frequencies in subsequent lines of treatment
The BRAF MT CRC patients of Eastern populations were also reported to share the same fate
as those in Western populations. A retrospective study [60] reported a BRAF mutation rate of
4.2% in 212 Chinese CRC patients. This study, which did not specifically examine the lines of
treatment administered, showed that BRAF MT was associated with advanced TNM (p<0.001),
more distant metastases (p=0.025), and worse OS (3-year OS: 16.7% in the BRAF MT subgroup
vs 73.2% in the BRAF WT subgroup; p<0.001). The BRAF mutation rate of 4.2% in the Chinese
population was found similar to the rates (1–7%) reported for Taiwanese and Japanese
populations [61–64].
BRAF MT is also associated with poor prognosis in other stages of CRC. A review in 2013 [65]
on seven studies that included stages I to IV CRC patients has concluded that BRAF mutation
served as an independent prognostic factor for reduced OS, disease-free survival (DFS), and
cancer-specific survival, especially in MSS CRC. One of the studies that included 911 stage II
to IV CRC patients demonstrated BRAF mutation to be associated with a poor 5-year OS
(BRAF MT vs WT, 47.5% vs 60.7%; p<0.01) [66]. Another study [47] looked at 1307 patients
with stage II to III CRC and reported reduced OS in BRAF MT group (HR=2.2; 95% CI=1.4–3.4;
p=0.0003).
To further analyse the impact of MSI status in the BRAF MT CRC patients, Samowitz et al. [66]
have shown that survival differs for stages II to IV CRC BRAF MT tumours with MSI compared
to MSS tumours. Poor prognosis was only demonstrated in MSS tumours (5YS: BRAF MT vs
WT, 16.7% vs 60.0%; log-rank p<0.01) from a multivariate analysis adjusted for age, stage, and
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tumour sites. MSI tumours were reported to have good prognosis regardless of BRAF MT
status, with 5YS 76.2% (with BRAF mutation) vs 75.0% (without BRAF mutation). Interestingly,
a recent retrospective Japanese study also studied the role of BRAF MT in MSI tumours [67].
They examined KRAS, BRAF, and MSI status in 813 patients with curatively resected, stage I
to III CRC. After adjusting for relevant variables, including MSI status, they reported that BRAF
MT were poor prognostic factors for DFS (HR=2.20; 95% CI=1.19–4.06) and OS (HR=2.30; 95%
CI=1.15–4.71) independent of MSI status. This small study, which excludes stage IV patients,
suggests that MSI-H tumours without BRAF mutation may have the best prognosis compared
to MSI-H tumours with BRAF mutation. MSS tumours with BRAF mutation would have the
worst prognosis.
In accordance with their aggressive nature, BRAF MT cancers have also been reported to have
poor PFS with sequential systemic treatments. A retrospective study on 1567 patients detected
a BRAF mutation rate of 8%. These BRAF MT patients had received a median of two later lines
of chemotherapy, with the median PFS for the first three lines of chemotherapy being 6.3, 2.5,
and 2.6 months, respectively [68]. Another smaller study had reported even shorter median
PFS (4.3 months) after first-line treatment in BRAF MT [69]. This observation highlights the
importance of considering early intensified treatment given the propensity for these patients
to not survive long enough for second- or third-line treatments.
Recently, other rare (<1%) subtypes of BRAF MT, which harbour mutations in codon 594 or
596, were reported to have markedly longer OS compared to BRAF V600E MT (median OS=62.0
vs 12.6 months; HR=0.36; 95% CI=0.20–0.64; p=0.002). These subtypes are noted to be MSS and
also differ in other molecular and clinical characteristics, being more frequently rectal in origin,
non-mucinous, and with no peritoneal spread [70].
4.2. Predictive role
Given that RAS MT are negative predictors of anti-epidermal growth factor receptor (EGFR)
therapies, the predictive role of BRAF MT for anti-EGFR agents has been of interest given the
relationship with RAS in the EGFR/RAS/RAF/MEK/ERK pathway. BRAF MT and its associated
resistance to anti-EGFR agents have been suggested by several retrospective analyses [71–73].
To date, the predictive role of BRAF MT on anti-EGFR agents remains unclear, in light of
differing conclusions from two separate meta-analyses [74, 75]. Pietrantonio et al. concluded
that BRAF MT might be a negative predictor for anti-EGFR agents, supporting the meta-
analysis by Yuan et al. [58]. This study included a pooled analysis of nine phase III trials and
one phase II trial and shown that cetuximab- or panitumumab-based therapy did not increase
the benefit of standard treatment versus best supportive care in RAS-WT/BRAF-MT CRC
patients. Overall, the addition of cetuximab or panitumumab did not significantly improve
the PFS (HR=0.88; p=0.33), OS (HR=0.91; p=0.63), and overall response rate [ORR; relative risk
(RR)=1.31; p=0.25] in this subgroup population [74]. However, another recent meta-analysis
reviewed seven RCTs for OS and eight RCTs for PFS and concluded on insufficient evidence
to justify the exclusion of anti-EGFR agents in the BRAF MT population [75]. Nevertheless,
these latest findings have supported the need for BRAF mutation assessment before the
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initiation of treatment to study and tailor the most effective strategies to the BRAF MT
population.
5. Treatment strategies
5.1. Triplet chemotherapy effect
BRAF MT has not been known to be a predictor of benefit from chemotherapy or anti-vascular
endothelial growth factor (VEGF) agents. The Italian TRIBE study [35] compared anti-VEGF
therapy, bevacizumab added to intensified triplet chemotherapy, fluorouracil, oxaliplatin, and
irinotecan (FOLFOXIRI), to standard first-line doublet chemotherapy with fluorouracil and
irinotecan (FOLFIRI) plus bevacizumab in 508 unresectable mCRC patients. The study
reported a higher response rate of 65% vs 53% with the triplet FOLFOXIRI and bevacizumab
arm. Reassuringly, there was no increase in fatal or serious adverse events.
The updated analyses of the same study reported a BRAF mutation rate of 7.5%. In the BRAF
MT group, there was a significant trend for better survival in the triplet arm compared to the
doublet arm (19.1 vs 10.8 months; HR=0.55). Significantly, this is the only regimen to have
resulted in a median OS of more than 15 months in the BRAF MT group compared to the more
often reported median of 4.4 to 14 months in most studies [29, 57]. It was proposed that
intensified triplet chemotherapy (FOLFOXIRI+bevaczicumab) is considered first line in the
BRAF MT group, who usually have aggressive cancers with limited ability to undergo a more
sequential approach to treat metastatic disease.
5.2. Maintenance treatment
A recent meta-analysis on five RCTs had failed to demonstrate a statistically significant OS
benefit (HR=0.93; 95% CI=0.85–1.02; p=0.12; I2=5%) with administering maintenance chemo‐
therapy versus complete treatment interruption after first-line therapy in unselected CRC [76].
The chemotherapy free interval in the group not using maintenance treatment was 3.9 months
(3.6–4.3 months). Nevertheless, the author had emphasized the importance of predictive
markers to guide the selection of patients who would benefit from the maintenance strategy.
Although not formally tested in the BRAF MT subgroup population, the maintenance strategy
might prove more favourable than the intermittent strategy given its known aggressive nature.
This is especially relevant given that the median reported PFS in BRAF MT as indicated
previously ranged from 4.3 to 6.3 months after first-line treatment [68, 69].
In terms of the choice for maintenance treatment, there is no current recommended standard.
However, practice trends could perhaps be extrapolated from the AIO KRK 0207 trial, which
confirmed the prognostic impact of mutation status [77]. In all patients (irrespective of BRAF
or RAS status), at a median follow-up of 27 months, the authors reported a time to failure of
strategy of 3.6, 6.2, and 4.6 months among all patients receiving no treatment, fluoropyrimidine
plus bevacizumab, or bevacizumab alone, respectively (p<0.001). However, in RAS/BRAF WT
patients, bevacizumab monotherapy was as effective as combination treatment (fluoropyra‐
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midine/bevacizumab) for maintenance. In contrast, in the RAS or BRAF MT subgroup, the
combination treatment was favoured, as single-agent bevacizumab was equivalent to no
maintenance at all.
6. Investigated treatments targeting EGFR/RAF/MEK
6.1. BRAF/MEK inhibitors
As mentioned above, RAS proteins normally activate BRAF along with A-RAF and C-RAF [78].
BRAF mutations lead to the constitutive activation of BRAF kinase activity, resulting in
phosphorylation and activation of the MEK kinases (MEK1 and MEK2). Once activated, MEK
kinases phosphorylate and activate ERK kinases, which phosphorylate a multitude of cellular
substrates involved in cell proliferation and survival (Figure 1).
RAF inhibitors, such as vemurafenib and dabrafenib, have produced response rates of 50 to
80% in melanomas that harbour the BRAF V600 mutations [79, 80]. This is disappointingly
contrasting to the response rate of only 5%, and median PFS of 2.1 months achieved in BRAF
MT CRC [81]. Previous observations have proposed that RAF inhibitor insensitivity in BRAF
MT CRC was driven by the feedback reactivation of the RAS/RAF/MEK/ERK signalling
cascade. In many BRAF MT CRC cell lines, EGFR-mediated activation of RAS and C-RAF was
observed to be the culprit [82, 83]. Solit et al. had also demonstrated the critical dependency
of BRAF MT colorectal cell lines and xenografts on MEK-ERK signalling, which renders them
highly sensitive to pharmacological MEK inhibition. Pharmacological MEK inhibition
completely abrogated tumour growth in BRAF MT xenografts, whereas RAS MT tumours were
only partially inhibited [84].
Many RAF inhibitor combinations were hence evaluated in clinical trials in recent years and
have shown promising results. A phase I to II clinical trial of combined RAF/MEK inhibition
with dabrafenib (150 mg BD) and trametenib (2 mg OD) in 43 BRAF MT CRC resistant to anti-
EGFR therapy produced partial responses in 12% and complete response in 2%. One patient
achieved a durable complete response exceeding 36 months. Additionally, 56% achieved stable
disease as the best confirmed response [85].
6.2. Dual and triplet targeting EGFR/BRAF/MEK inhibitors
The observations above have also led to a number of studies assessing the combined blockade
at other sites in the EGFR pathway in addition to RAF/MEK inhibition. It was observed that
the dual inhibition of anti-EGFR therapy in combination with RAF inhibition in resistant cell
lines might still produce a lower degree of mitogen-activated protein kinase (MAPK) pathway
inhibition in BRAF MT CRC compared to single-agent RAF inhibitors in BRAF MT melanoma
patients. Dabrafenib and panitumumab doublet was trialled with a response rate of (partial
and complete response) 2/20 (10%) and stabilised disease in 16/20 (80%) as the best overall
response [86]. Another study examined the combination of vemurafenib (BRAF-inhibitor) and
panitumumab in 15 patients. Two (13%) patients reported partial responses lasting 40 and 24
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weeks, respectively. Eight (53%) patients stable disease lasting more than 6 months [87]. A
phase II study studied dual inhibition with encorafenib (BRAF inhibitor) and cetuximab with
26 patients. Encorafenib and cetuximab doublet was reported to produce an overall RR
(complete and partial) of 23.1% with a median PFS of 3.7 months. The most common treatment-
related grade 3/4 adverse events associated with this doublet regimen were fatigue and
hypophosphatemia (8% each) [88].
Encouragingly, the triplet combination of EGFR/RAF/MEK inhibition in BRAF MT CRC
reported an improved response rate (26% complete and partial) in 35 patients compared to the
doublet inhibition. The triplet regimen had also stabilised disease in 57%. The most common
adverse events reported were diarrhoea (60% grade 1/2 and 9% grade 3) and dermatitis
acneiform (47% grade 1/2 and 9% grade 3) [86].
6.3. Acquired resistance to EGFR/RAF/MEK targeted therapies
Although trials have demonstrated early efficacies of combination targeted therapies in these
BRAF MT patients, attention was brought towards their eventual treatment resistance and
disease progression. A group in Harvard recently compared pretreatment and postprogres‐
sion BRAF MT CRC tumour biopsies by whole exome sequencing (WES) to examine the related
changes that could explain treatment resistance in these cases [89]. They have identified four
possible acquired molecular mechanisms that could lead to resistance to combination treat‐
ments with RAF/MEK and RAF/EGFR. These four mechanisms include (1) KRAS exon 2
mutation (G12D and G13D), (2) KRAS WT amplification [confirmed by fluorescence in situ
hybridisation (FISH) to be ~25-fold overexpression], (3) BRAF MT allele amplification, and (4)
MEK1 mutation. These alterations converge on the MAPK pathway reactivation and promote
resistance.
Interestingly, the group also discovered an ERK inhibitor that retained the ability to suppress
MAPK signalling and overcome each of these mechanisms identified [89]. In conjunction with
these findings, early-phase clinical trials are currently incorporating ERK inhibitors as
potential future treatment strategies for BRAF MT CRC.
6.4. Other possible EGFR/RAF targeted combination treatments
6.4.1. Vemurafenib/irinotecan/cetuximab combination
The phase I vemurafenib/irinotecan/cetuximab triplet study reported a RR of 35% (partial
response) in 18 mCRC patients with a median PFS of 7.7 months. The most common adverse
effects were fatigue (94%), diarrhoea (89%), nausea (83%), and rash (78%). Following this, a
U.S. cooperative group randomised phase II trial (NCT01787500) of irinotecan and cetuximab
±vemurafenib in BRAF-mutated mCRC (SWOG 1406) is now ongoing [90].
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7. Alternative target signalling pathways
Although our increasing understanding of the complexity of the EGFR/RAF pathway has led
to some advances in our understanding of possible mechanisms of resistance to BRAF
inhibition, additional complex interactions with related pathways are likely to be involved,
including the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, mammalian target of
rapamycin (mTOR), and Wnt signalling.
7.1. PI3K/AKT and mTOR pathway
The PI3K/AKT pathway is an alternative resistance mechanism to BRAF inhibition in BRAF
MT CRC. Approximately 40% of CRC have been shown to have alterations in one of eight PI3K
pathway genes. These mutations are almost always mutually exclusive to each other [91]. In
addition, BRAF mutation co-exists with PIK3CA mutations in 13% and PTEN mutations in 22%
of CRC [37]. Compared to BRAF MT melanoma cell lines, BRAF MT CRC cell lines seemed to
also display a higher rate of PI3K/AKT pathway activation. These cell lines were reported to
be less sensitive to the BRAF inhibitor, vemurafenib [92].
Based on the above observations, the combination triplet inhibition treatment was studied with
encorafenib (BRAF inhibitor), cetuximab, and PI3K inhibitor (alpelisib) in 28 patients and
reported an overall RR of 32.1% with a median PFS of 4.3 months. The most common grade
3/4 adverse events reported were hyperglycemia (11%) and increased lipase (7%) [88].
Sustained PI3K/mTOR activity was demonstrated also by Corcoran et al. [82] in BRAF MT
CRC cell lines upon BRAF inhibition. Pleasingly, a potent growth-inhibitory effect was recently
observed in xenografts of BRAF MT CRC with the combined BRAF/PI3K/mTOR inhibition
[93].
7.2. Wnt/β-catenin pathway
A study by Lemieux et al. demonstrated the Wnt/β-catenin pathway (Figure 3) as a potential
novel target in MEK/ERK signalling involved in CRC tumourigenesis [94]. The Wnt/β-catenin
pathway is activated via the binding of Wnt1 protein to the G-protein coupled receptor,
Frizzled. After the activation by Wnt1, Dishevelled protein (Dsh) induces the dissociation of
the destruction complex that usually degrades β-catenin. Without the destruction complex,
β-catenin is accumulated in the cytoplasm and transported to the nucleus to act as a transcrip‐
tional coactivator of transcription factors as shown in Figure 4. The aforementioned destruc‐
tion complex comprises Axin (A), adenomatous polyposis coli (APC), and glycogen synthase
kinase 3 (GSK3β). In the absence of Wnt1 activation, the destruction complex phosphorylates
the downstream ubiquinating process. Here, the β-transducin repeat containing protein
(βTrCP) binds β-catenin, ubiquinating it and marks it for degradation by the proteasome.
Although there is conflicting literature with regards to the role of MAPK signalling in activat‐
ing Wnt/β-catenin pathway, this group found Wnt signalling induction in high-grade BRAF
MT tumours. Their data also show that the oncogenic activation of KRAS/BRAF/MEK
signalling stimulates the canonical Wnt/β-catenin pathway, which in turn promotes intestinal
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tumour growth and invasion. This has in turn sparked trial designs to incorporate Wnt
signalling as a treatment strategy.
Figure 4. Wnt/β-catenin pathway.
8. Other possible therapeutic mechanisms
Recently, a number of other early studies have reported additional potential mechanisms of
targeted treatment, which had shown promise in BRAF MT CRC xenografts or cell line studies.
8.1. Multi-targeted angiokinase inhibitor (dovitinib)
Dovitinib is a multi-target angiokinase inhibitor with activity against fibroblast growth factor
receptors (FGFRs), platelet-derived growth factor receptors (PDGFRs), and VEGF receptors,
which participate in tumour growth, survival, angiogenesis, and vascular development.
Although not effective in vitro, in vivo studies have shown the inhibition of BRAF MT xenografts
tumours with dovitinib. Lee et al. proposed that this observation is secondary to its angiogen‐
esis-suppressing effect and could be a novel approach to improve the outcome of CRC patients
in whom FGFR is overexpressed or amplified [95].
8.2. Proteasome inhibitor (carfilzomib)
A novel use of proteasome inhibitors (carfilzomib, bortezomib), known more for utility in
haematological malignancy, has shown promising preclinical results in BRAF MT CRC [96].
Zecchin et al. have observed increased sensitivity of BRAF MT CRC to carfilzomib, whereas
WT cells were significantly less affected (p<0.05). This response seemed to be independent of
the phosphatase and tensin homologue (PTEN) or retinoblastoma protein (RB1) expression
status in CRC. The mechanism of this activity was explained by the higher accumulation rate
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of ubiquitinated proteins in MT cells with respect to WT. It was speculated that this is
secondary to the non-oncogenic addiction of BRAF MT cells to the protein degradation
function of proteasome to counterbalance the proteotoxic stress induced by the MT protein.
Interestingly, carfilzomib was also found to have antagonistic effects with the RAF inhibitor,
vemurafenib, and was proposed as a possible alternative treatment to BRAF/MEK inhibition.
8.3. microRNA (miR-145)
miR-145, a short RNA molecule of microRNA gene, which was observed to have tumour
suppressor function, was found to be down-regulated in vemurafenib-resistant BRAF MT CRC
cell lines [97]. Peng et al. reported that the overexpression of miR-145 increased the sensitivity
of BRAF MT CRC cell lines both in vitro and in vivo and could be used as a potential therapeutic
target.
8.4. In situ cancer vaccine (Allostim)
AlloStim is an innovative design based on immunotherapy principles. It is derived from the
blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T cells
are initially separated from the blood and differentiated and expanded for 9 days in culture to
make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4 h with
antibody-coated microbeads. The cells with the beads still attached are suspended in infusion
media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care. A
phase I study was completed in May 2011 and a phase II/III study is due to recruit in 2016. It
involves an in situ (in the body) cancer vaccine step that combines killing a single metastatic
tumour (usually liver metastasis) lesion by the use of cryoablation to cause the release of
tumour-specific markers to the immune system and then injecting bioengineered allogeneic
immune cells (AlloStim) into the lesion as an adjuvant to modulate the immune response and
educate the immune system to kill other tumour cells wherever they reside in the body [98].
8.5. Apoptosis regulator (BCL-2/BCL-XL) inhibitor (Navitoclax)
Apoptosis regulator (BCL-2/BCL-XL) inhibitor (Navitoclax) was explored as a novel approach
in sensitising BRAF MT CRC to mTOR inhibition. The results showed that this combination
strategy leads to efficient apoptosis in specifically KRAS and BRAF MT but not WT CRC cells
[99]. These data showed promising results with the combination strategy of apoptosis
regulator inhibitors with mTOR inhibitors in BRAF MT CRC.
9. Ongoing trials for BRAF MT CRC
Many phase I/II trials are currently ongoing for BRAF MT mCRC. Most of them focus on the
RAS/RAF/MEK/ERK signalling pathway, trialling combination targeted treatments. Table 5
lists these available trials.
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Trial name/Reg Phase Trialed agents Status
NCT01543698 I/II RAF inhibitor (dabrafenib)+MEK inhibitor
(trametenib)+CDK4/6 inhibitor (LEE011)
Recruiting
NCT 01719380 IB/II RAF inhibitor (LGX818)+cetuximab+PI3K inhibitor
(BYL-719) vs LGX818+ BYL-719
Recruiting
NCT01902173 I/II Dabrafenib+trametenib: in stage IIIC+IV CRC Recruiting
NCT02034110 II Dabrafenib+trametenib: BRAF MT rare cancers Recruiting
NCT00265824 III Avastin±erlotinib: maintenance treatment
in unresectable CRC
Closed;
awaiting for
results
NCT02175654
(PREVIUM)
II Regorafenib: single-agent second-line
post-FOLFOXIRI+Avastin
Recruiting
NCT01750918 I/II Dabrafenib+trametenib+panitumumab Recruiting
NCT01787500 I Vemurafenib+cetuximab+irinotecan Recruiting
S1406 II Cetuximab+irinotecan±vemurafenib Recruiting
NCT01596140 I Vemurafenib+mTOR inhibitor
(everolimus/temsirolimus)
Recruiting
NCT02041481 I MEK inhibitor+FOLFOX: CRC failing
standard treatment
Recruiting
NCT02380443 IIB Allostim (in situ cancer vaccine): third-line
treatment in KRAS/BRAF MT CRC
Pending
NCT02278133 IB/II Wnt ligand inhibitor (WNT974), RAF inhibitor
and cetuximab
Recruiting
NCT01351103 I Wnt ligand inhibitor (LGK974) Recruiting
Table 5. Ongoing trials in BRAF MT CRC
10. Conclusion
The BRAF V600E MT CRC typically presents with right-sided proximal high-grade mucinous
tumours in older women and may arise from serrated polyps. Molecularly, they are associated
with more MLH1 methylation, MSI, and CIMP. This small subset of CRC, which generally
affects approximately 10% of CRC patients, remains a challenging group with poor response
to both anti-EGFR and standard doublet chemotherapy. This CRC subgroup is typically
aggressive, has short median PFS between sequential lines of treatments, and emphasises the
need to use effective treatments early. New evidence suggests that triplet chemotherapy with
FOLFOXIRI could be considered in suitable patients with or without bevacizumab as first-line
treatment. Many trials are currently studying the effective combinations of targeted treatments
involving BRAF and MEK inhibitors in this subgroup and ways to overcome resistance.
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